1365 related articles for article (PubMed ID: 31801180)
41. [Study of immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine and oral poliovirus vaccine].
Lu L; Li XM; Liu DL; Zhang HR; Zhang ZJ; Wang HH; Liu F; Ning ZQ; Zhang LW; Chu P; Xie YT; Xu Y; Li J; Pang XH; Deng Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):510-3. PubMed ID: 22943896
[TBL] [Abstract][Full Text] [Related]
42. World wide experience with inactivated poliovirus vaccine.
Bonnet MC; Dutta A
Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
[TBL] [Abstract][Full Text] [Related]
43. [VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS IN RUSSIAN FEDERATION DURING THE PERIOD OF CHANGES IN VACCINATION SCHEDULE (2006-2013 yy.)].
Ivanova OE; Eremeeva TP; Morozova NS; Shakaryan AK; Gmyl AP; Yakovenko ML; Korotkova EA; Chernjavskaja OP; Baykova OY; Silenova OV; Krasota AY; Krasnoproshina LI; Mustafina AN; Kozlovskaja LI
Vopr Virusol; 2016; 61(1):9-15. PubMed ID: 27145594
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
45. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.
Estívariz CF; Anand A; Gary HE; Rahman M; Islam J; Bari TI; Wassilak SG; Chu SY; Weldon WC; Pallansch MA; Heffelfinger JD; Luby SP; Zaman K
Lancet Infect Dis; 2015 Aug; 15(8):898-904. PubMed ID: 26093980
[TBL] [Abstract][Full Text] [Related]
46. Oral and inactivated poliovirus vaccines in the newborn: a review.
Mateen FJ; Shinohara RT; Sutter RW
Vaccine; 2013 May; 31(21):2517-24. PubMed ID: 22728224
[TBL] [Abstract][Full Text] [Related]
47. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.
Sáez-Llorens X; Clemens R; Leroux-Roels G; Jimeno J; Clemens SA; Weldon WC; Oberste MS; Molina N; Bandyopadhyay AS
Lancet Infect Dis; 2016 Mar; 16(3):321-30. PubMed ID: 26719058
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB).
Cowley D; Sari RM; Handley A; Watts E; Bachtiar NS; At Thobari J; Satria CD; Bogdanovic-Sakran N; Nirwati H; Orsini F; Lee KJ; Kirkwood CD; Soenarto Y; Bines JE
Vaccine; 2019 Nov; 37(49):7233-7239. PubMed ID: 31607604
[TBL] [Abstract][Full Text] [Related]
49. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules.
Parent du Châtelet I; Merchant AT; Fisher-Hoch S; Luby SP; Plotkin SA; Moatter T; Agboatwalla M; McCormick JB
Vaccine; 2003 Apr; 21(15):1710-8. PubMed ID: 12639494
[TBL] [Abstract][Full Text] [Related]
50. Fractional dose compared with standard dose inactivated poliovirus vaccine in children: a systematic review and meta-analysis.
Mashunye TR; Ndwandwe DE; Dube KR; Shey M; Shelton M; Wiysonge CS
Lancet Infect Dis; 2021 Aug; 21(8):1161-1174. PubMed ID: 33939958
[TBL] [Abstract][Full Text] [Related]
51. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
[TBL] [Abstract][Full Text] [Related]
52. Coverage estimates and patterns of inactivated poliovirus vaccine (IPV) use prior to and during the polio eradication endgame, Jinan City, China, 2010-2015.
Chang C; Zhang J; Zhou J; Cao R; Song K; Liu C; Zhang X; Geng X; Liu X; Li C
Hum Vaccin Immunother; 2016 Nov; 12(11):2749-2752. PubMed ID: 27437792
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.
Miller MA; Sutter RW; Strebel PM; Hadler SC
JAMA; 1996 Sep; 276(12):967-71. PubMed ID: 8805731
[TBL] [Abstract][Full Text] [Related]
54. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines.
Ogra PL
Ann N Y Acad Sci; 1995 May; 754():97-107. PubMed ID: 7625685
[TBL] [Abstract][Full Text] [Related]
55. Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Heng Hung L; Aleman Y; Mesa I; Garcia G; Sutter RW
Clin Infect Dis; 2018 Oct; 67(suppl_1):S51-S56. PubMed ID: 30376088
[TBL] [Abstract][Full Text] [Related]
56. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
Famulare M; Selinger C; McCarthy KA; Eckhoff PA; Chabot-Couture G
PLoS Biol; 2018 Apr; 16(4):e2002468. PubMed ID: 29702638
[TBL] [Abstract][Full Text] [Related]
57. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.
Saleem AF; Mach O; Quadri F; Khan A; Bhatti Z; Rehman NU; Zaidi S; Weldon WC; Oberste SM; Salama M; Sutter RW; Zaidi AK
Vaccine; 2015 Jun; 33(24):2757-63. PubMed ID: 25917673
[TBL] [Abstract][Full Text] [Related]
58. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-12.
Iqbal S; Shi J; Seib K; Lewis P; Moro PL; Woo EJ; Shimabukuro T; Orenstein WA
Lancet Infect Dis; 2015 Oct; 15(10):1175-1182. PubMed ID: 26289956
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
[TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
